Funding for this research was provided by:
National Institute for Health Research (North Thames CLAHRC infrastructure award, without a number; for £212,747)
Received: 27 March 2018
Accepted: 19 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: The process evaluation and qualitative study work has ethical approval from the London Research Ethics Committee, Queen Mary University of London (QMREC1799a: 25.08.16; & QMERC2015/29a and QMERC2015/29b: 30.07.15 respectively), with the former also approved by the NHS Health Research Authority (16/HRA/4398: 13.10.2016). All interview participants provide written informed consent.The quantitative ITS evaluations only use anonymised data, arising from the usual care of women so individual consent of women is not required. This decision and study is approved by the Chair of the NHS London Camden Research Ethics Committee, as an evaluation of usual care.
: Not applicable.
: AH and MJ were DVA IRIS AEs, at time of original IRIS trial; and are now both funded to facilitate commissioning of IRIS in the UK, with MJ the CEO of IRISi. Positive trial findings would support their career development. GF is on the IRISi board. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.